The combined effect of generating strong CD8+ T cell responses using a transplantable OVA-expressing tumor model, IL-33 alarmin signalling and IFN-I production (for 48 hrs) led to more potent and specific anti-tumor immunity and subsequent tumor control superior to that of the replication deficient rLCMV without neutralizing antibody production (62). Here, IL33 is linked to neoplasm.